People  |  News  |

Technology Review: Gene Editing

Technology Review: Gene Editing

Dummy Image

Edition one of phacilitate's technology review series examines gene editing approaches by viral and non-viral methods and where to access these services

The manipulation of DNA and specific gene editing is one of the great scientific breakthroughs of our time. However, delivering gene modifying material into cells has posed some challenges, particularly when it comes to the large amounts required for advanced therapies and their required doses.

This report focuses on the various methods of delivery, their relative advantages and disadvantages, as well as the companies that are offering them.

Read more to understand:

  • Who’s offering non-viral approaches to cell engineering and how they are disrupting the cell membrane
  • The key characteristics and qualities of the four main vector types
  • A review of the organisations providing viral vectors for clinical and commercial needs
150 150 Anemocyte

Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961